- Home
- RAPT vs OABI Comparison
RAPT vs OABI Comparison
Compare RAPT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- OABI
- Stock Information
- Founded
- RAPT 2015
- OABI 2012
- Country
- RAPT United States
- OABI United States
- Employees
- RAPT N/A
- OABI N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- OABI Health Care
- Exchange
- RAPT Nasdaq
- OABI Nasdaq
- Market Cap
- RAPT 194.2M
- OABI 230.3M
- IPO Year
- RAPT 2019
- OABI N/A
- Fundamental
- Price
- RAPT $13.18
- OABI $1.58
- Analyst Decision
- RAPT Buy
- OABI Strong Buy
- Analyst Count
- RAPT 5
- OABI 3
- Target Price
- RAPT $33.60
- OABI $6.67
- AVG Volume (30 Days)
- RAPT 117.5K
- OABI 378.3K
- Earning Date
- RAPT 08-07-2025
- OABI 08-06-2025
- Dividend Yield
- RAPT N/A
- OABI N/A
- EPS Growth
- RAPT N/A
- OABI N/A
- EPS
- RAPT N/A
- OABI N/A
- Revenue
- RAPT N/A
- OABI $23,027,000.00
- Revenue This Year
- RAPT N/A
- OABI N/A
- Revenue Next Year
- RAPT N/A
- OABI $44.99
- P/E Ratio
- RAPT N/A
- OABI N/A
- Revenue Growth
- RAPT N/A
- OABI 6.05
- 52 Week Low
- RAPT $5.67
- OABI $1.22
- 52 Week High
- RAPT $26.56
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- RAPT 63.64
- OABI 38.75
- Support Level
- RAPT $11.19
- OABI $1.51
- Resistance Level
- RAPT $13.66
- OABI $1.73
- Average True Range (ATR)
- RAPT 0.75
- OABI 0.12
- MACD
- RAPT 0.19
- OABI -0.01
- Stochastic Oscillator
- RAPT 86.53
- OABI 13.21
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.